Richard Browne
Cardiovascular Disease · Charlotte, NCNPI 1720095508
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $326,287 of the $378,831 with a category attached, or 86.1%. Johnson & Johnson accounts for 64.0% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $196,712 and has fallen 98.2% since, to $3,493 in 2025. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 476 payments — averaging $795.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$242K
- Sanofi-aventis U.S. LLC$53K
- Esperion Therapeutics, Inc.$52K
- Boston Scientific$13K
- Astellas Pharma US Inc$5K
- Regeneron Healthcare Solutions, Inc.$4K
- plus $9K from 24 others
What the payments were for
- Consulting fees$15,5184%
- Speaking & faculty fees$326,28786%
- Travel & lodging$24,8757%
- Food & beverage$12,0233%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 234 | $242,492 |
| Sanofi-aventis U.S. LLC | 56 | $53,206 |
| Esperion Therapeutics, Inc. | 54 | $51,965 |
| Boston Scientific | 36 | $12,898 |
| Astellas Pharma US Inc | 6 | $5,494 |
| Regeneron Healthcare Solutions, Inc. | 13 | $3,901 |
| Novo Nordisk | 1 | $2,748 |
| Lantheus Medical Imaging, Inc. | 3 | $2,129 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $542 |
| Abiomed | 4 | $384 |
| Amgen | 8 | $354 |
| AstraZeneca | 6 | $295 |
| Cleerly, Inc. | 2 | $274 |
| Irhythm Technologies, Inc. | 10 | $260 |
| Medtronic | 4 | $253 |
| Janssen Scientific Affairs, LLC | 3 | $227 |
| Novartis | 3 | $210 |
| Kestra Medical Technology Services, Inc. | 2 | $188 |
| Idorsia Pharmaceuticals US Inc | 3 | $187 |
| Shockwave Medical, Inc | 1 | $109 |
| E.r. Squibb & Sons, L.L.C. | 5 | $107 |
| Pfizer | 1 | $106 |
| Akcea Therapeutics, Inc. | 1 | $103 |
| Otsuka America Pharmaceutical, Inc. | 1 | $96 |
| Abbott | 1 | $83 |
| Bayer | 1 | $63 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $57 |
| Atricure, Inc. | 1 | $54 |
| Genentech, Inc. | 1 | $30 |
| Cardiva Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$240,726
- PRALUENT$55,934
- NEXLIZET$51,465
- NEXLETOL$51,465
- Watchman$12,242
- LEXISCAN$5,484
- Definity$2,124
- Impella$378
- BRILINTA$239
- Cleerly Ischemia$220
- Cleerly Labs$220
- Repatha$216
- Assure WCD$147
- CG Future$146
- WATCHMAN FLX$137
- ENTRESTO$120
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$109
- TEGSEDI$103
How this compares
$378,831 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Other cardiovascular disease in Charlotte
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Sanjeev GulatiCharlotte$406K
- Rohit MehtaCharlotte$189K
- Brian PowellCharlotte$160K
- Nicole Cyrille-SupervilleCharlotte$115K
- Noreen KellyCharlotte$84K
- Dermot PhelanCharlotte$76K
- Charles SimontonCharlotte$73K
- Satish MisraCharlotte$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.